Industry Requests for Technology
Location & Contact
6431 Fannin Street,
Houston, Texas 77030
PO Box 20708,
Houston, Texas 77225
The Office of Technology Management is often approached by companies looking for specific technologies. We provide the following list of inquiries. Should you have a technology of interest, please contact us.
Request 8.1 Therapeutic monoclonal antibodies having shown promising results in animal models or early stage clinical study.
Request 8.2 Novel active immunotherapy products having shown promising results in animal models or early stage clinical study.
Request 8.3 Adjuvant (to viral vectors and to proteins) having shown promising results in animal models or early stage clinical study.
Request 8.4 Novel targets in infectious diseases having shown promising results in animal models or early stage clinical study.
Request 8.5 Novel tumor associated antigens having shown promising results in animal models or early stage clinical study.
Request 8.6 New bio-inspired/biomimetic technologies that have become available for bone, tissue engineering, cosmetics (skin/biopolymers), ceramics (self-assembling, biomedical and semiconductor materials) and adhesives (textiles and/or medical) applications.
Request 8.7 Oncology, allergy and autoimmune diseases, especially toll-like receptors (TLRs).
Request 8.8 Novel small molecule or small peptide In the areas of cancer or cardiovascular and be at an early stage of development (lead compound or pre-lead), not looking for a new use of an old molecule.
Request 8.9 Research-stage therapeutics for rare genetic and metabolic diseases.
Request 8.10 New drug targets (genes, receptors, enzymes), screening assays, cell lines, animal models, lead compounds, etc. that could be helpful in enabling identification and development of novel small molecule human therapeutics. Areas of highest interest to them are metabolic diseases (diabetes, obesity, lipid regulation), autoimmune diseases (IBD, SLE), inflammation, allergy, asthma, neuropathic/chronic pain, and anti-viral targets (HIV and HCV only). Also, some interest in new drug targets for urinary incontinence (neurogenic overactive bladder), osteoporosis and kidney diseases (nephropathies, chronic nephritis). Only those technologies containing exceptional and novel science will be considered (no interest in new uses for old drugs or new delivery forms of known drugs).
Request 8.11 Early predictors of toxicity/ADME, RNAi and siRNA technologies, high-throughput screening (HTS) technologies, proteomic-related technologies, suppliers of compound libraries and structure-based lead generation technologies (virtual screening, HTS X-ray crystallography, etc.).
Request 8.12 Nanotechnology listings where 'self-assembly' is featured.
Request 8.13 Biomimetic and bio-inspired research disclosures. Our primary areas of interest are: Life Sciences (Bone, Dental, Cartilage, Tissue Engineering, Nanomaterials/Technologies),Engineering (Optical, Acoustical, Mechanical (e.g. Robotics, Rehabilitation), Intelligent Software, Systems and Control), Near Infrared Cardiovascular and CNS Diagnostic Biomarkers or Optical Probes/Targets, Near Infrared Imaging Devices/Methods; and/or Near Infrared Contrast Agents.
Request 8.14 Novel compounds for the treatment of serious bacterial infections such as tuberculosis, MRSA, anthrax etc.
Request 8.15 Contrast agents (microbubbles). Technologies that utilize contrast agents as a therapeutic/diagnostic tool (especially for ultrasound applications), drug-delivery, cardiology, oncology, ablation, surgery.
Request 8.16 A method for treating humans with microbial (bacterial, fungal or viral) infections that are resistant to available treatments. The compounds we are looking for will disrupt the growth or reproduction of bacteria, fungi or viri via a pathway that has not been used previously - a novel mechanism of action.
Request 8.17 Medical implant technologies (materials, structures, and/or devices), including but not limited to dental/craniofacial implants.
Request 8.18 Robotics-related (materials/hardware/software) disclosures.
Request 8.19 Monoclonal and polyclonal antibodies and research products in the areas of DNA repair, stem cells, hypoxia, neuroscience, cancer, apoptosis, autophagy, metabolism, and cholesterol res